Class / Patent application number | Description | Number of patent applications / Date published |
514601000 | Sulfonamides (i.e., Q-(O=)S(=O)-N, wherein Q is a substituent and wherein any substituent attached to the nitrogen will be referred to as E) | 66 |
20090082457 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK - This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases. | 03-26-2009 |
20090163594 | Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors - The invention provides assays and methods for determining whether a compound inhibits gamma secretase in a substrate specific manner. The invention provides an isolated cell wherein the cell stably expresses APP and at least one gamma secretase substrate other than APP. The invention provides assays and methods comprising contacting a cell with gamma secretase and detecting production of Abeta, detecting production of intracellular domain (ICD), and detecting a signal from a reporter gene under transcriptional control of the ICD. The invention also provides compounds that inhibit gamma secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds. | 06-25-2009 |
20100004339 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists - The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful. | 01-07-2010 |
20100035996 | GLUCOSE METABOLISM STIMULATING AGENT - A compound of the formula I: | 02-11-2010 |
20110060049 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME - This invention concerns N-(2-arylamino) aryl sulfonamide compounds which are inhibitors of MEK including crystalline polymorphic forms which exhibit a specific powder x-ray diffraction profile and/or a specific differential scanning calorimetry profile. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer, hyperproliferative diseases and inflammatory conditions. The invention also concerns methods of making the compounds and compositions described herein. | 03-10-2011 |
20120016034 | Polymorphic Form Of N-(S)-(3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-6-Methoxyphenyl)-1-(2,- 3-Dihydroxypropyl)Cyclopropane-1-Sulfonamide And Uses Thereof - Disclosed herein, in certain embodiments, is a crystalline polymorph form A of N-(S)-(3,4-difluoro-2 -(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. Further disclosed herein, in certain embodiments, are pharmaceutical compositions comprising the crystalline polymorph form A of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl) -1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. | 01-19-2012 |
20140303253 | Polymorphic Form of N-(S)-(3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-6-Methoxyphenyl)-1-(2,- 3-Dihydroxypropyl)Cyclopropane-1-Sulfonamide and uses thereof - Disclosed herein, in certain embodiments, is a crystalline polymorph form A of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. Further disclosed herein, in certain embodiments, are pharmaceutical compositions comprising the crystalline polymorph form A of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. | 10-09-2014 |
514602000 | Q contains benzene ring | 46 |
514603000 | Nitrogen in Q | 24 |
20080262089 | Process for the Preparation of Tamsulosin - The invention includes an improved process for producing tamsulosin comprising reacting 5-(2-aminopropyl)-2-methoxybenzenesulfonamide with 2-(o-ethoxyphenoxy)ethyl bromide in an organic phosphite solvent to obtain tamsulosin. Optically pure (R)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide can be employed to produce optically pure (R)-tamsulosin product. The organic phosphite solvent utilized in the reaction can include tri-alkyl phosphites such as triethyl phosphite, trimethyl phosphite, and tributyl phosphite. Additionally, processes for producing tamsulosin having a low concentration of by-product contaminants, such as 5-((R)-2-{Bis-[2-(2-ethoxyphenoxy)ethyl]amino}-propyl)-2-methoxybenzenesulfonamide, and the use of such by-products to monitor the chemical purity of tamsulosin, are provided. | 10-23-2008 |
20080312328 | DEUTERIUM-ENRICHED TAMSULOSIN - The present application describes deuterium-enriched tamsulosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 12-18-2008 |
20090137681 | Sirtuin Inhibiting Compounds - Provided herein are compositions and methods for treating or preventing cancer and autoimmune diseases. Compositions comprise a sirtuin inhibitory compound that decreases the activity of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell or a molecule with a sirtuin inhibitory compound that decreases the activity of a sirtuin and thereby reduces the life span of a cell, kills the cell or renders it susceptible to certain cell stresses including radiation and chemotherapy. Other methods include treating pathogens expressing a sirtuin. | 05-28-2009 |
20090170950 | Inhibitors Of Neurotrypsin - The invention relates to a method for determining whether a compound is a neurotrypsin inhibitor, characterized in that the compound is incubated together with neurotrypsin, a variant thereof or a fragment comprising the protease domain and with a protein or peptide comprising agrin, a variant thereof or a fragment comprising the α- or the β-cleavage site of agrin, in an aqueous buffer solution, and the amount of cleavage of agrin is measured. Additionally, the invention relates to inhibitors of neurotrypsin found by this method, in particular to compounds of formula | 07-02-2009 |
20090221711 | TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS - A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: | 09-03-2009 |
20090234014 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation - There is provided compounds of formula (I), wherein R | 09-17-2009 |
20090264533 | Methods and Compositions for Modulating RHO-Mediated Gene Transcription - The present invention is directed to methods and compositions methods and compositions for determining and inhibiting gene transcription in mammalian cells. The invention relates to novel inhibitors of rho-mediated gene transcription and to compounds that may be used as therapeutic agents. | 10-22-2009 |
20090306212 | Compositions and Methods for Treating Diabetes and Neuropsychological Dysfunction - The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders. | 12-10-2009 |
20100063154 | POLYMORPHS OF ACYL SULFONAMIDES - The application discloses novel polymorphic crystalline forms of 2-[4-Bromo-3-(3-chloro-5-cyano-phenoxy)-2-fluoro-phenyl]-N-(2-chloro-4-propionylsulfamoyl-phenyl)-acetamide, sodium salt (Ib) | 03-11-2010 |
20100093865 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - Provided are sulphur-linked compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions. | 04-15-2010 |
20100093866 | Pharmaceutical Formulations - The invention relates to the use of magnesium stearate to inhibit or reduce chemical degradation of an active ingredient substance in a formulation comprising a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical degradation. | 04-15-2010 |
20100317739 | HISTONE DEACETYLASE INHIBITORS - Novel histone deacetylase inhibitors, including novel fluorescent histone deacetylase inhibitors, are described. Methods for making and using the same, e.g., to treat cancer, are provided. | 12-16-2010 |
20110237677 | Inhibitors - The invention relates to inhibitors of tissue transglutaminase II activity and their use as a tocolytic agent. | 09-29-2011 |
20120065270 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF - Compounds of formula (I) and pharmacologically acceptable salts and pro-drugs wherein: | 03-15-2012 |
20120088838 | METHODS FOR MAINTAINING EFFECTIVE PLASMA CONCENTRATIONS OF A PHARMACEUTICAL - The present invention provides a sustained-release pharmaceutical composition, characterized in that there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (C | 04-12-2012 |
20120264827 | SULFANYLAMIDE DERIVATIVES, USES THEREOF AND COMPOSITIONS COMPRISING THEM - The present invention concerns a family of sulfanilamide derivatives of formula (I) as anticonvulsant agents, where R is selected from optionally substituted C | 10-18-2012 |
20130178533 | COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE - The present invention relates to a composition for diagnosing, treating, and preventing liver disease, more particularly a composition for diagnosing liver disease comprising a material for measuring the grade of TM4SF5 (transmembrane 4 L six family member 5 or four-transmembrane L6 superfamily member 5) protein, a kit for diagnosing liver disease comprising the said composition, a method for providing information necessary for diagnosing liver disease composed of the following steps; measuring the level of TM4SF5 protein and the expressions and phosphorylations of TM4SF5 expression related signaling proteins; and comparing the measured levels with those of the normal control, a method for screening a material for treating liver disease, and a composition for treating or preventing liver disease comprising a material inhibiting TM4SF5 protein expression or the expressions and phosphorylations of TM4SF5 expression related signaling proteins. | 07-11-2013 |
20140031429 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS - Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. | 01-30-2014 |
20140163110 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS - Compounds of the formula Ia or Ib: | 06-12-2014 |
20140206768 | CHOLINE SALT OF AN ANTI-INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUND - 6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide choline, solid pharmaceutical compositions and oral dosage forms that contain said compound, and a method of using such compositions and oral dosage forms to treat people who have inflammatory, obstructive or allergic conditions and diseases are disclosed. | 07-24-2014 |
20150031770 | Pharmaceutical Formulations of HDAC Inhibitors - This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxyl-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc. | 01-29-2015 |
20150073054 | INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES - Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed. | 03-12-2015 |
20160052876 | CRYOPYRIN INHIBITORS FOR PREVENTING AND TREATING INFLAMMATION - Inhibitors that are anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as heart failure and autoimmune diseases. | 02-25-2016 |
20160152561 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | 06-02-2016 |
514604000 | Q is monocyclic | 22 |
20080214672 | Treatment of Asthma with Aryl Sulfonamides - The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating asthma. | 09-04-2008 |
20080255240 | Sulfonamide Derivatives - Novel sulfon amide derivatives are chemical uncouplers useful e.g. for the treatment of obesity. | 10-16-2008 |
20080275127 | Arylsulfonamido-substituted hydroxamic acid derivatives - α-Amino hydroxamic acid derivative of the formula I, | 11-06-2008 |
20090076152 | Novel Compounds Active as Muscarinic Receptor Antagonists - The invention relates to compounds of formula | 03-19-2009 |
20100041760 | MONOARYL AMINOTETRALINES - The invention is concerned with the compounds of formula I: | 02-18-2010 |
20100041761 | NEW HALO ACTIVE AROMATIC SULFONAMIDE ORGANIC COMPOUNDS AND ODOR CONTROL USES THEREFOR - Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. The most widely used halogen sulfonamide organic compound for these applications is Chloramine-T. This invention deals with the new use of discovered compositions of matter, halo active aromatic sulfonamide organic compounds and use of solutions of these compounds as, odor control agents. The odor control solutions may be buffered to a predetermined pH. The odor control compositions may further incorporate small percentages of low molecular weight alcohols and wetting agents. | 02-18-2010 |
20100113600 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND - A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs). The 3D pharmacophore model is used as a template in virtual screening compounds for new ARDAs. ARDA compounds and compounds that strongly inhibit the growth of human prostate LNCaP cells. The compounds may be used in compositions and methods of inhibiting cell proliferation of a cancer and methods of preventing or treating cancer, including prostate cancer. | 05-06-2010 |
20110065799 | UROKINASE INHIBITORS, PRODUCTION AND USE THEREOF - The invention relates to novel inhibitors of urokinase and to their preparation and use for the therapy, prophylaxis and diagnosis of a tumor, in particular for reducing the formation of tumor metastases. | 03-17-2011 |
20110077305 | 5-LIPOXYGENASE INHIBITORS - The use of compounds of the formula (I) Ar | 03-31-2011 |
20110251284 | HALO ACTIVE AROMATIC SULFONAMIDE ORGANIC COMPOUNDS AND USES THEREFOR - Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. This disclosure deals with the use of halo active aromatic sulfonamide organic compounds as odor control and/or biocidal agents in a cleaning solution for use with bovines and other dairy animals. | 10-13-2011 |
20110301241 | NEW HALO ACTIVE AROMATIC SULFONAMIDE ORGANIC COMPOUNDS AND USES THEREFOR - Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. This disclosure deals with the use of halo active aromatic sulfonamide organic compounds as odor control and/or biocidal agents in a cleaning solution for use with bovines and other dairy animals. | 12-08-2011 |
20120329877 | Cycloalkyl-dione Derivatives And Methods Of Their Use - The present invention is directed to compounds of formula I: | 12-27-2012 |
20130090385 | NOVEL SPECIFIC CASPASE-10 INHIBITORS - The invention relates to compounds of the general formula (I) wherein R1, R2, R3, R4, R5, R6, i and j have the meanings given in claim 1, and to the use thereof as caspase-10 inhibitors, especially for the treatment of diabetic retinopathy. | 04-11-2013 |
20130165523 | COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS - The present invention concerns a method for treating and/or preventing a disease in a subject comprising the step of administrating an effective amount of a compound of formula I to a subject in need thereof. | 06-27-2013 |
20130331456 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS - The present invention is related to the development of compounds and methods for inhibiting viral infection in a mammal. A pseudotype virus was developed for use in a high throughput assay for identifying nonpeptidic small molecule inhibitors that prevent viral entry into a host cell. | 12-12-2013 |
20140005271 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR INFECTIOUS DISEASES, CONTAINING m-3M3FBS, WHICH IS ACTIVATOR OF PHOSPHOLIPASE C, AS ACTIVE INGREDIENT | 01-02-2014 |
20140206769 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX - The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure. | 07-24-2014 |
20140336261 | METHODS FOR DETERMINING AGGRESSIVENESS OF A CANCER AND TREATMENT THEREOF - The invention generally relates to methods for determining aggressiveness of a cancer and treatment thereof. Certain aspects of the invention provide methods that involve conducting an assay on a lipid droplet in order to detect an amount of a biomarker within the lipid droplet, and determining aggressiveness of a cancer based upon the amount of the biomarker within the lipid droplet. Other aspects of the invention provide methods for treating a cancer that involve administering an agent that blocks storage of cholesteryl ester in a lipid droplet. | 11-13-2014 |
20150297542 | Powder composition for disinfection of the teats of dairy animals - A powder composition for the post-milking teat disinfection of dairy animals is described. In particular, said composition has proven to be advantageously effective as bactericidal agent, while without causing irritation or reddening of the skin. | 10-22-2015 |
20160031805 | CYCLOALKYL-DIONE DERIVATIVES AND METHODS OF THEIR USE - The present invention is directed to compounds of formula I: wherein A is n is 0, 1, or 2; m is 0 or 1; R | 02-04-2016 |
20160038444 | MODULATON OF CELLULAR DNA REPAIR ACTIVITY TO INTERCEPT MALIGNANCY - Disclosed herein are methods for identifying compounds that enhance base excision repair, as well as compounds identified thereby and methods of using such compounds in the interception of malignancy, i.e. the prevention of progression of a disease from a state of susceptibility to active disease. Exemplified compounds are acetohexamide and related compounds, as well as benserazide and analogs thereof. Exemplified malignancies are those of human breast cells carrying mutations, in particular, SUM149 cells and HCC1937 cells, which cells carry BRCA1 mutations. | 02-11-2016 |
20160081951 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION - The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof. | 03-24-2016 |
514605000 | Q is acyclic and benzene ring in a substituent E | 13 |
20090030083 | Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury - N-(2-aryl-propionyl)-sulfonamides of general formula (I): | 01-29-2009 |
20090270508 | GluR2 receptor modulators - The present invention provides for compositions and methods for modulating the GluR2 receptor. It is based, at least in part, on the discovery, by X-ray crystallography, that a known GluR2 agonist binds to the receptor in two different orientations, thereby diminishing its potency. The present invention provides for structural alternatives in which alternative binding possibilities are substantially eliminated. | 10-29-2009 |
20100099769 | BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF, AND USE THEREOF FOR MEDICAL PURPOSES - The benzylamine derivative represented by the formula below and a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutical containing the derivative or the pharmaceutically acceptable acid addition salt thereof, and a therapeutic or prophylactic agent for pollakiuria or urinary incontinence containing the derivative or the pharmaceutically acceptable acid addition salt thereof are provided. The benzylamine derivative of the present invention and the pharmaceutically acceptable acid addition salt thereof have less possibility of occurrence of side effects than known compounds, and show a better therapeutic effect against pollakiuria or urinary incontinence, so that they can be used as excellent therapeutic or prophylactic agents for pollakiuria or urinary incontinence. | 04-22-2010 |
20100152297 | COMPOSITION FOR REGULATING CELLULAR SENESCENCE COMPRISING N-[2-(CYCLOHEXY-LOXYL)-4-NITROPHENYL]-METHANESULFONAMIDE - The present invention relates to a composition for inhibiting cellular senescence, comprising N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide. During the progression of cellular senescence, the expression of COX-2 was decreased, whereas the enzymatic activity of COX-2 was increased, and the cellular senescence regulatory effects of the three selective COX-2 inhibitors had no connection with the concentration of intracellular reactive oxygen species, the activity of NF-κB and the amounts of p53 and p21 proteins. Rather, it was found that the three selective COX-2 inhibitors regulated the expression of caveolin-1 at the transcriptional level and regulated the intracellular total cholesterol concentration, and these results were closely connected with the cellular senescence regulatory effects of the three selective COX-2 inhibitors. | 06-17-2010 |
20100204333 | Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor - Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.0% Sodium lauryl sulphate as dissolution medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (C | 08-12-2010 |
20110124733 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DIABETES, OBESITY, DYSLIPIDEMIA OR METABOLIC SYNDROME COMPRISING BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID - A method of treatment or prophylaxis of diabetes, obesity, dyslipidemia or metabolic syndrome, includes administering an effective amount of a benzylamine derivative represented by Formula (I): | 05-26-2011 |
20110275719 | NOVEL TRIFLUOROMETHYLSULFONAMIDE GAMMA SECRETASE INHIBITOR - The present invention is directed to a novel trifluoromethylsulfonamide derivative which inhibits the processing of APP by the putative γ-secretase and thus is useful in the treatment or prevention of Alzheimer's disease. This compound possesses favorable pharmacokinetic properties in higher species (rhesus) and thus can be dosed on an intermittent dosing regiment (e.g., once weekly). When dosed on such a regiment the compound exhibits significant and continuous Aβ lowering without the manifestation of Notch associated gastrointestinal toxicity for extended periods, e.g., 7 days. Pharmaceutical compositions and methods of use are also included. | 11-10-2011 |
20120088839 | COMPOSITION FOR REGULATING CELLULAR SENESCENCE COMPRISING [N-2-(CYCLOHEXYLOXYL)-4-NITROPHENYL]-METHANESULFONAMIDE - The present invention relates to a composition for inhibiting cellular senescence, comprising N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide. | 04-12-2012 |
20120202884 | INHIBITORS OF CXCR1/2 AS ADJUVANTS IN THE TRANSPLANT OF PANCREATIC ISLETS - The invention relates to CXCR1 and/or CXCR2 inhibitors for the preparation of a medicament for use as an adjuvant in the transplant of pancreatic islets in Type 1 diabetes patients. In particular, the compounds that can be used according to the invention have the following formula (I) in which R and R′ are as defined in the description. | 08-09-2012 |
20130131180 | N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICAMENT CONTAINING SAME - A compound represented by the following general formula (I) which has ADAM17 inhibitory activity, or a salt thereof, or a solvate thereof: | 05-23-2013 |
20140011881 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. | 01-09-2014 |
20150011639 | SULFONAMIDES FOR THE PREVENTION OF DIABETES - The use of sulfonamides of formula (I) | 01-08-2015 |
20190142772 | Sotalol Compositions and Uses of the Same | 05-16-2019 |